Medtronic Settles States ' Probe Into Infuse Marketing for $12 Million Medtronic Settles States ' Probe Into Infuse Marketing for $12 Million

Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday.Reuters Health Information

Source: Medscape Medical News Headlines - December 14, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news